+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Depression - Pipeline Review, H1 2019

  • ID: 4778157
  • Drug Pipelines
  • May 2019
  • Region: Global, Global
  • 558 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adamed Sp zoo
  • Bionomics Ltd
  • Clera Inc
  • Hua Medicine Shanghai Ltd
  • MedinCell SA
  • Otsuka Holdings Co Ltd
  • MORE
Depression - Pipeline Review, H1 2019

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2019, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 16, 34, 36, 2, 78, 13 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adamed Sp zoo
  • Bionomics Ltd
  • Clera Inc
  • Hua Medicine Shanghai Ltd
  • MedinCell SA
  • Otsuka Holdings Co Ltd
  • MORE
Introduction

Depression - Overview

Depression - Therapeutics Development

Depression - Therapeutics Assessment

Depression - Companies Involved in Therapeutics Development

Depression - Drug Profiles

Depression - Dormant Projects

Depression - Discontinued Products

Depression - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Depression, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Adamed Sp zoo, H1 2019

Depression - Pipeline by Addex Therapeutics Ltd, H1 2019

Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Alkermes Plc, H1 2019

Depression - Pipeline by Allergan Plc, H1 2019

Depression - Pipeline by Amorsa Therapeutics Inc, H1 2019

Depression - Pipeline by Anavex Life Sciences Corp, H1 2019

Depression - Pipeline by Angelini Group, H1 2019

Depression - Pipeline by Atai Life Sciences AG, H1 2019

Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Axsome Therapeutics Inc, H1 2019

Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2019

Depression - Pipeline by Bionomics Ltd, H1 2019

Depression - Pipeline by BioXcel Therapeutics Inc, H1 2019

Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2019

Depression - Pipeline by Bristol-Myers Squibb Co, H1 2019

Depression - Pipeline by Calico LLC, H1 2019

Depression - Pipeline by Celgene Corp, H1 2019

Depression - Pipeline by Cellix Bio Pvt Ltd, H1 2019

Depression - Pipeline by Celon Pharma SA, H1 2019

Depression - Pipeline by Cerecor Inc, H1 2019

Depression - Pipeline by Clera Inc, H1 2019

Depression - Pipeline by Clexio Biosciences Ltd, H1 2019

Depression - Pipeline by Delpor Inc, H1 2019

Depression - Pipeline by Denovo Biopharma LLC, H1 2019

Depression - Pipeline by Douglas Pharmaceuticals Ltd, H1 2019

Depression - Pipeline by Eisai Co Ltd, H1 2019

Depression - Pipeline by Eli Lilly and Co, H1 2019

Depression - Dormant Projects, H1 2019

Depression - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Depression, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Acadia Pharmaceuticals Inc
  • Adamed Sp zoo
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • Alkermes Plc
  • Allergan Plc
  • Amorsa Therapeutics Inc
  • Anavex Life Sciences Corp
  • Angelini Group
  • Atai Life Sciences AG
  • Avanir Pharmaceuticals Inc
  • Axsome Therapeutics Inc
  • Azevan Pharmaceuticals Inc
  • BioXcel Therapeutics Inc
  • Bionomics Ltd
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Calico LLC
  • Celgene Corp
  • Cellix Bio Pvt Ltd
  • Celon Pharma SA
  • Cerecor Inc
  • Clera Inc
  • Clexio Biosciences Ltd
  • Delpor Inc
  • Denovo Biopharma LLC
  • Douglas Pharmaceuticals Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Fabre-Kramer Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • GliaCure Inc
  • H. Lundbeck AS
  • Hua Medicine Shanghai Ltd
  • Impel NeuroPharma Inc
  • Intas Pharmaceuticals Ltd
  • Intra-Cellular Therapies Inc
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Jina Pharmaceuticals Inc
  • Johnson & Johnson
  • KemPharm Inc
  • Kissei Pharmaceutical Co Ltd
  • Krenitsky Pharmaceuticals Inc
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Lixte Biotechnology Holdings Inc
  • Luye Pharma Group Ltd
  • Mapi Pharma Ltd
  • Mapreg SAS
  • MedinCell SA
  • Medlab Clinical Ltd
  • Meta-IQ ApS
  • Mitsubishi Tanabe Pharma Corp
  • Navitor Pharmaceuticals Inc
  • Neuralstem Inc
  • NeuroNascent Inc
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • Omeros Corp
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • Protagenic Therapeutics Inc
  • Relmada Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • SK Biopharmaceuticals Co Ltd
  • Sage Therapeutics Inc
  • Shenox Pharmaceuticals LLC
  • Sosei Heptares
  • Sound Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Sunovion Pharmaceuticals Inc
  • Supernus Pharmaceuticals Inc
  • Suven Life Sciences Ltd
  • Syntropharma Ltd
  • Takeda Pharmaceutical Co Ltd
  • Trevena Inc
  • VistaGen Therapeutics Inc
  • Yungjin Pharm Co Ltd
  • Zysis Ltd
Note: Product cover images may vary from those shown
Adroll
adroll